Online inquiry

IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4960MR)

This product GTTS-WQ4960MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets GP gene. The antibody can be applied in Ebola virus infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NP_066246.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 911829
UniProt ID Q05320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4960MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9613MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ13836MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ5142MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ7279MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ7702MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ869MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ5677MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ2703MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW